A Selective NMR Probe to Monitor the Conformational Transition from Inactive to Active Kinase by Xie, Qian et al.
Biochemistry, Biophysics and Molecular Biology
Publications Biochemistry, Biophysics and Molecular Biology
9-2014
A Selective NMR Probe to Monitor the





Iowa State University, bfulton@iastate.edu
Amy H. Andreotti
Iowa State University, amyand@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/bbmb_ag_pubs
Part of the Molecular Biology Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
bbmb_ag_pubs/25. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Biochemistry, Biophysics and Molecular Biology at Digital Repository @ Iowa State
University. It has been accepted for inclusion in Biochemistry, Biophysics and Molecular Biology Publications by an authorized administrator of Digital
Repository @ Iowa State University. For more information, please contact digirep@iastate.edu.
A Selective NMR Probe to Monitor the Conformational Transition
from Inactive to Active Kinase
Qian Xie, D. Bruce Fulton, and Amy H. Andreotti*
Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, Iowa 50011, United
States
*S Supporting Information
ABSTRACT: Kinases control many aspects of cellular
signaling and are therefore therapeutic targets for numerous
disease states. Monitoring the conformational changes that
drive activation and inactivation of the catalytic kinase core is a
challenging experimental problem due to the dynamic nature
of these enzymes. We apply [13C] reductive methylation to
chemically introduce NMR-active nuclei into unlabeled
protein kinases. The results demonstrate that solution NMR
spectroscopy can be used to monitor speciﬁc changes in the
chemical environment of structurally important lysines in a
[13C]-methylated kinase as it shifts from the inactive to active
state. This approach provides a solution based method to complement X-ray crystallographic data and can be applied to nearly
any kinase, regardless of size or method of production.
Kinase inhibitor development1,2 has driven signiﬁcantinvestment in understanding the precise structural
features that control kinase activity. Most of our knowledge
regarding kinase structure comes from X-ray crystallography, a
technique that provides spectacular views of the molecular
determinants that control the catalytic activity of these
enzymes.3−5 Despite its power to resolve atomic level details,
X-ray diﬀraction captures static structural snapshots; the
intermediates along the trajectory of a conformational
transition are often lost. Moreover, use of X-ray crystallography
to solve numerous drug or ligand bound structures can be
laborious or not feasible. To complement and enhance available
X-ray derived structural information, solution-based techniques
must continue to be developed to adequately interrogate kinase
structure−function relationships.
Here we report a simple and rapid NMR approach to assess
the conformational preferences of any kinase in solution. Using
[13C]-labeled formaldehyde, we have used reductive methyl-
ation chemistry6 to introduce a spectroscopic probe into the
active site at the β3 strand lysine of a model kinase. The
chemical environment surrounding the β3 lysine changes on
transition from inactive to active kinase,7−9 providing a direct
reporter of the activation trajectory. The method can be applied
to any kinase regardless of expression system and creates a
novel platform to study kinase regulatory mechanisms under a
range of solution conditions. In addition to providing insight
into how exogenous proteins and/or second messengers aﬀect
kinase regulation, the method can be used to directly measure
the eﬀect of disease-causing mutations or small molecule
modulators on the conformational preferences of the kinase
active site.
Src tyrosine kinase was chosen as a model system for NMR
method development due to its well understood regulatory
mechanism.10 The Src domain structure consists of two Src
Homology domains, SH3 and SH2, a catalytic kinase domain
and a C-terminal tail containing a regulatory tyrosine (Tyr527)
(Figure 1a). In the autoinhibited conformation of Src,11,12
phosphorylated Tyr527 binds to the Src SH2 domain
intramolecularly and the Src SH3 domain interacts with the
linker spanning the SH2 and kinase domains (Figure 1b).
Dephosphorylation of Tyr527, and/or exogenous ligand
binding to SH3 and SH2, liberates the kinase domain from
the conformational restraints imposed by the SH3/2 domains,
and the kinase domain shifts to the active conformation13−17
(Figure 1b). It is also established that the isolated kinase
domains of Src family members (lacking the SH3-SH2 region)
are active.18
Kinases share the β3 strand lysine in the N-lobe that
protrudes toward the active site, coordinates ATP, and forms a
salt bridge with the conserved glutamate on the C-helix. In
crystal structures of the autoinhibited form of Src,12 the C-helix
is out of the active site, and the distance between the Lys ε-
amine group and the Glu carboxylate group (Lys295/Glu310)
is 14 Å (Figure 1c). In structures of active Src,19 the C-helix
abuts the active site of the kinase domain leading to a short, 3.7
Å, distance between the Lys295 and Glu310 side chains (Figure
1d). The chemical environment of Lys295 diﬀers between
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active and inactive conformations, and NMR chemical shift can
therefore serve as a reporter of kinase activation status.
The ε-NH3
+ protons of lysine are not good NMR probes due
to rapid exchange with water and resulting unfavorable
relaxation properties. However, if the lysine side chain is
modiﬁed in a manner that introduces a nonexchangeable NMR
probe and retains the electrostatic properties of the native side
chain, the conformational transitions between active and
inactive kinases could be monitored in solution. Protein
reductive methylation results in two methyl groups covalently
attached to the ε-NH2 of lysine side chains as well as the amino
terminal α-NH2 (Figure 2a, inset).
6 The positive charge on the
lysine side chain is maintained, and so ion pair interactions are
largely maintained.20 The favorable relaxation properties of
CH3 allow NMR analysis of both conformationally constrained
and mobile lysine side chains.21−23
Two forms of the Src kinase, SH3-SH2-kinase domain
(SH3SH2KD) and the isolated Src kinase domain (KD), were
expressed and puriﬁed to homogeneity (Supplementary Figure
S1a). We use a modiﬁed form of Src SH3SH2KD that contains
a tail sequence optimized for intramolecular SH2 binding
favoring the inactive conformation.24 We subjected Src
SH3SH2KD and Src KD to reductive methylation by [13C]-
labeled formaldehyde using ammonia borane as the reducing
agent.25 SDS-PAGE, MALDI-TOF mass spectrometry, and
MS/MS analysis were used to characterize the methylated Src
SH3SH2KD and KD proteins and conﬁrmed dimethylation of
primary amines and Lys295 in particular (Supplementary
Figure S1a,b). Circular dichroism (CD) spectra for the
methylated and unmethylated Src SH3SH2KD and KD
proteins are similar (Supplementary Figure S1c,d), indicating
methylation does not aﬀect secondary structural elements.
Moreover, methylation of 15N-labeled Src KD allowed
acquisition of a 1H−15N heteronuclear single quantum
coherence (HSQC) spectrum of the modiﬁed protein.
Comparison of this two-dimensional NMR data set with that
of unmethylated, 15N-labeled Src kinase domain shows that
almost all resonances overlap for the two proteins, and only a
small subset of peaks resonate at diﬀerent frequencies,
consistent with the overall kinase domain fold remaining intact
following lysine methylation (Supplementary Figure S1e).
Kinase activity of methylated Src was dramatically reduced
compared to unmodiﬁed enzymes (Supplementary Figure S2a).
The loss of activity is likely due to impaired ATP coordination
in the active site, since in addition to its interaction with
Glu310, the β3 strand Lys295 coordinates the α- and β-
phosphates of ATP. Indeed, addition of the stable ATP
analogue, AMP-PNP, to 15N-labeled samples of unmodiﬁed and
methylated Src KD shows loss of binding to the methylated
protein at concentrations that match the ATP concentration
used in the activity assays (Supplementary Figure S2b,c). There
is ample precedence, most notably in the pseudokinase
literature,26 for catalytically incompetent kinases being able to
populate both active and inactive conformations. Moreover,
inactive kinases are often employed for biophysical experi-
ments,7,27 and so, despite the loss of catalytic activity for the
methylated kinase, we proceeded with analysis using NMR
spectroscopy.
We acquired a [1H,13C] HSQC spectrum for the [13C]-
methylated Src SH3SH2KD protein (Figure 2a). This experi-
ment measures the 1H and 13C resonance frequencies of each
[13C] C−H functional group. A number of 1H−13C crosspeaks
are evident in the spectrum and correspond to the methyl
resonances of the dimethylated lysine side chains and to
concentrated buﬀer components due to 13C at natural
abundance. Based on previously published work,20 the dimethyl
resonances are centered at a 13C chemical shift of ∼45 ppm.
The dimethyl peaks that resonate downﬁeld in the 1H
dimension are largely degenerate and likely correspond to
methyl groups attached to solvent-exposed lysines that
experience similar chemical environments (Figure 2b). In
contrast, several methyl resonances are well-resolved and
shifted upﬁeld, suggesting the presence of unique lysine side
chain environments within Src.
Assignment of the β3 strand lysine (Lys295 in Src) was
accomplished by mutation of Lys295 to methionine in the Src
SH3SH2KD protein. Methylation of the mutant protein
followed by acquisition of the [1H,13C] HSQC spectrum
revealed a single missing resonance that is assigned to Lys295
in the original spectrum (Figure 2b,c). Additional peaks are
shifted upﬁeld in the 1H dimension, suggesting that at least one
other lysine residue exists in a unique environment. Systematic
mutation of candidate lysines, followed by methylation and
acquisition of [1H,13C] HSQC data for each mutant, led to
assignment of the 1H−13C cross peak at 2.25 and 42.5 ppm as
dimethylated Lys315 (Figure 2b,d). The dimethylated α-NH2
was assigned by introducing a thrombin cleavage site between
the N-terminal hexaHis tag and the ﬁrst residue of Src
SH3SH2KD. The methylated protein was then treated with
thrombin and further puriﬁed using a Ni resin to remove
uncleaved protein and the resulting His tag peptide. The
[1H,13C] HSQC spectrum for Src SH3SH2KD lacking the N-
terminus reveals a single missing resonance, allowing
unequivocal assignment of the dimethylated amino-terminus
(α-NH2) (Figure 2b,e). The same mutagenesis approach was
used to assign the corresponding resonances in the [1H,13C]
HSQC spectrum of Src KD (Supplementary Figure S3).
Figure 1. Src structure. (a) Src kinase domain structure. (b) Schematic
of the conformational equilibrium between inactive (left) and active
(right) states. (c) Crystal structure of the inactive Src kinase (2SRC)
showing the conserved Lys295 and Glu310. (d) Crystal structure of
the active Src kinase (1Y57) showing the short distance between
Lys295 and Glu310.
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The resolved methyl resonances of Lys295 and 315 provide
two separate probes within the Src SH3SH2KD protein to
monitor conformational changes during the course of Src
activation. Lys315 is one and a half turns away from Glu310 on
the C-helix and in the autoinhibited Src structure projects away
from the N-lobe of the kinase domain toward the linker
between SH2 and kinase domains, making extensive contacts
with Trp260 (Figure 3a). Src activation leads to a large shift in
the position of the SH3/SH2 domains and the SH2-kinase
linker region (Figure 3b). Peptide ligands that target the Src
SH3 and/or SH2 domains compete with the autoinhibited
form and activate the Src kinase.28 We titrated two peptides,
VSLARRPLPPLP and pYEEIE (ligands for the Src SH3 and
SH2 domains, respectively), into the NMR sample containing
[13C]-methylated Src SH3SH2KD (Figure 3c,d). Addition of
increasing concentration of SH3 ligand causes spectral changes;
speciﬁcally, the peak corresponding to Lys295 disappears over
the course of SH3 ligand titration, due to line broadening and/
or chemical shift change that results in overlap with the
neighboring peak (Figure 3c). The Lys315 methyl peak exhibits
slow exchange behavior as SH3 ligand concentration increases
(Figure 3c). Saturation with SH3 peptide ligand results in the
emergence of a new peak at a 1H frequency of 2.28 ppm and
complete loss of the original Lys315 signal present in the
spectrum of free Src SH3SH2KD.
In a separate titration, the SH2 peptide ligand, pYEEIE, was
added to the methylated Src SH3SH2KD sample. Stepwise
addition of the pYEEIE peptide causes no spectral change over
a range of ligand concentrations (Supplementary Figure S4).
This result can be reconciled with the fact that we are using a
modiﬁed Src construct that contains a high aﬃnity tail sequence
surrounding pTyr527; the isolated pYEEIE phosphopeptide
does not compete with the intramolecular ligand for SH2
binding at the concentrations used in the NMR experiment. We
therefore explored whether the pYEEIE ligand might compete
with the pTyr527 for binding to the SH2 domain of
SH3SH2KD in the context of SH3 peptide ligand. Using the
SH3SH2KD sample that is already saturated with SH3 ligand
(last panel in Figure 3c), we added increasing concentration of
the pYEEIE peptide. In this titration, addition of SH2 ligand
results in further chemical shift perturbation of the Lys315
methyl resonance (Figure 3d). The ﬁnding that ligand
occupancy of the SH3 domain in SH3SH2KD aﬀects
accessibility of the SH2 domain in the intact Src protein is
reminiscent of crosstalk between regulatory domains explored
previously using other methods.29−32
Figure 2. Chemical modiﬁcation and NMR data acquisition and assignment. (a) [1H,13C] HSQC spectrum of [13C]-methylated Src SH3SH2KD.
Dimethylated lysine resonances are labeled “DM”, and NMR signals from buﬀer components are labeled (identiﬁed by acquiring the identical
[1H,13C] HSQC spectrum on buﬀer alone). The inset shows the structure of the protonated, dimethyl lysine epsilon amino group. (b) Select region
of the [1H,13C] HSQC spectrum of methylated Src SH3SH2KD. Dimethyl Lys295, Lys315, and the dimethylated amino terminus (αNH2) are
assigned on the basis of mutational data shown in panels c−e. (c−e) Superposition of [1H,13C] HSQC spectra of [13C]-methylated SH3SH2KD
(black) and Lys295Met mutant (red) (c); Lys315Arg mutant (red) (d); and SH3SH2KD lacking the amino-terminus (e). In panels c−e the missing
resonance in the mutant spectrum is indicated by the arrow.
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Upon saturation of SH3SH2KD with both SH3 and SH2
ligands, the dimethyl lysine region diﬀers dramatically from the
[1H,13C] HSQC spectrum acquired for free SH3SH2KD
(Figure 3c,d (bolded spectra)). Superposition of the SH3/
SH2 ligand-saturated SH3SH2KD spectrum with that of the
isolated Src kinase domain (KD) shows an exact correspond-
ence in the resolved region (Figure 3e). This ﬁnding provides
direct evidence that SH3 and SH2 ligand binding results in
release of the Src kinase domain, which then adopts the active
conformation present in the free kinase domain. Finally, we
subjected the ligand-saturated SH3SH2KD sample to repeated
dialysis to remove peptide ligands and determine the
reversibility of the conformational shift. Acquisition of a
[1H,13C] HSQC spectrum following dialysis shows that the
resonance belonging to Lys315 reappears at its original
chemical shift (Figure 3d), suggesting that reduced peptide
ligand binding to the SH3 and SH2 domains leads to a
conformational shift toward the inactive conformation.
The proof-of-principle experiment in Figure 3 demonstrates
that NMR spectroscopy, using [13C]-methylated lysine side
chains as probes, reports on the conformational ensemble of
the Src kinase domain under a range of conditions. In light of
the inconvenient exchange regime/chemical shift degeneracy of
the Lys295 resonance, the well-resolved Src Lys315 peak
provides a convenient, alternative signal that monitors the
complete conformational transition between inactive and active
Figure 3. Conformational transition from inactive to active Src monitored by NMR. (a,b) Structures of (a) inactive Src (2SRC) and (b) active Src
(1Y57) showing Lys295 and Lys315 in the N-lobe of the kinase domain. Glu310 and Trp260 are also shown, as are portions of the SH3 and SH2
domains on the “backside” of the Src kinase domain. (c) SH3 peptide ligand (NAc-VSLARRPLPPLP-NH2) was titrated into 135 μM [
13C]-
methylated Src SH3SH2KD, and [1H,13C] HSQC spectra were acquired at each titration point. The left-most spectrum is [13C]-methylated Src
SH3SH2KD with no ligand (bold outline), and the following six spectra contain increasing molar equivalents of peptide ligand. Boxes throughout
panels c and d show the resonance frequencies of Lys295 and Lys315 in the absence of ligand. Peak assignments are indicated in the ﬁrst spectrum,
and the asterisk indicates an unidentiﬁed peak. (d) SH2 peptide ligand (Caﬀeic acid-pYEEIE) titrated into the [13C]-methylated Src SH3SH2KD
sample containing 10 molar equiv of SH3 peptide ligand (last panel in part c). The bolded spectrum is Src SH3SH2KD protein in the presence of
saturating amounts of both SH3 and SH2 domain ligands. The ﬁnal panel shows the spectrum acquired after dialysis of the ligand-saturated Src
SH3SH2KD sample. (e) (left) [1H,13C] HSQC spectrum of the [13C]-methylated Src kinase domain (Src KD). (right) Superposition of the Src KD
spectrum (blue) with the [1H,13C] HSQC spectrum of SH3SH2KD after saturation with both SH3 and SH2 ligands (black).
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Src (Figure 3c,d). While Src Lys315 is not strictly conserved
across kinase families, we wondered whether other kinases
would similarly exhibit multiple resolved dimethyl lysine
resonances that, in the event of unfavorable spectral properties
for the conserved β3 lysine, could be used to monitor the
complete conformational transition between inactive and active
kinase. To this end, we expressed and puriﬁed two additional
kinases, Btk and Csk, and subjected these proteins to reductive
methylation. Acquisition of [1H,13C] HSQC spectra for
methylated Btk and Csk (Figure 4a,b) shows that these kinases,
like Src, exhibit multiple nondegenerate dimethyl resonances.
Moreover, a comparison of the isolated Btk and Csk kinase
domains to their corresponding multidomain proteins
(SH3SH2KD) shows spectral diﬀerences in the region of the
resolved dimethyl lysine resonances (Figure 4a,b) consistent
with activity diﬀerences, and hence conformational diﬀerences,
in the kinase domain induced by the presence of the non-
catalytic domains.33,34 While residue-speciﬁc assignments and
characterization of these systems are beyond the scope of the
current work, these data suggest that the presence of multiple
spectroscopic probes may be a general feature of reductively
methylated kinases.
We next took advantage of two Btk inhibitors, B43 and
dasatinib; both bind to the kinase active site yet stabilize
distinct conformational states. X-ray crystallography has shown
that binding of B43 stabilizes the kinase inactive conformation,
while dasatinib stabilizes the active state.35 We titrated these
small molecules into separate samples of the [13C]-methylated
Btk KD and acquired [1H,13C] HSQC spectra at increasing
concentrations of inhibitor (Figure 4c,d). The resulting series
of spectra indicate that the resolved dimethyl lysine resonances
are sensitive to inhibitor binding in the Btk active site.
Moreover, the end points of the two titrations are diﬀerent,
suggesting that B43 and dasatinib favor diﬀerent kinase domain
conformational states in solution consistent with the co-crystal
structures.35 These data suggest that, in addition to allosteric
modulators (Figure 3), reagents that target the kinase active site
can also be assessed using the combination of 13C reductive
lysine methylation and NMR spectroscopy described here. It
should be noted, however, that the proximity of the β3 lysine to
the kinase active site means that its dimethyl resonance
frequency may be aﬀected by both the conformational changes
induced within the kinase domain and direct binding of the
inhibitor, complicating spectral analysis. For this reason, the
presence of an alternative dimethyl lysine peak outside of the
active site, such as Lys315 in Src, may be particularly valuable in
studies focused on active site inhibitors.
In conclusion, NMR data acquired using a lysine methylated
sample provide a spectral signature of the Src kinase activation/
inactivation trajectory. The data report on the conformational
ensemble that is present in solution, enabling the identiﬁcation
of intermediates along the course of kinase activation. We
suggest this method will allow investigators to gain insight into
the conformational ensemble of any pharmaceutically impor-
tant, full-length protein kinase in solution, many of which rely
on eukaryotic expression systems for production, are diﬃcult to
isotopically label, and show limited yield. The approach can be
used to assess how allosteric and direct interactions, between a
Figure 4. Extension of method to additional kinases. (a,b) Dimethyl lysine region of spectra acquired for [13C]-methylated Btk (a) and Csk (kinase
domains and SH3-SH2-kinase domain constructs) (b). Non-degenerate resonances are indicated with a dashed box. (c) Btk kinase domain drug
titrations. A 100 μM sample of [13C]-methylated Btk kinase domain (Tyr551 is mutated to Glu to correspond to protein used in the reported crystal
structure35) was titrated with either B43 (top row) or dasatinib (bottom row) at the indicated molar equivalents. [1H,13C] HSQC spectra shown are
acquired before addition of drug or at each titration point. The Btk kinase domain also carries the Y617P mutation that facilitates bacterial
expression.39
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kinase and its binding partner, be it a substrate, a regulator, or
an adaptor protein, drives the conformation of the kinase
domain toward the active or inactive state. Similarly, the
method provides a rapid analysis of conformational status of a
kinase upon inhibition with a small molecule, complementing
previous applications of 13C NMR spectroscopy to kinase drug
discovery.36 Finally, insight into how speciﬁc disease-causing
mutations within or outside of a kinase domain aﬀect
conformational preferences of the catalytic site can also be
gained with this method. Overall, this method promises to
provide deeper insight into the molecular basis of kinase
regulatory mechanisms.
■ METHODS
Protein Production. Src proteins were coexpressed with YopH
and puriﬁed as described.37 15N-Labeled proteins were expressed in
minimal media as described previously.38 Reductive methylation
followed previous published protocols.25 All mutations were
introduced using site-directed mutagenesis kit (Strategene) and
veriﬁed by sequencing at the ISU DNA Synthesis and Sequencing
Facility.
Characterization of Methylated Kinases. For trypsin digestion,
15 μL of 50 mM NH4HCO3 and 1.5 μL of 100 mM DTT were added
to 10 μL of 0.8 mg/mL kinase sample, and the volume was adjusted to
27 μL with H2O. The mixture was incubated at 95 °C for 5 min, and 3
μL of 100 mM iodoacetamide was added and incubated in the dark at
RT for 20 min. Next, 1 μL of sequencing grade modiﬁed trypsin
(Promega) at 0.1 μg/μL was added and incubated for 3 h at 37 °C.
Digested samples were analyzed by MALDI-TOF and MS/MS using
Q-Star XL quadrupole-TOF tandem mass spectrometer (ABI) in the
Protein Facility at Iowa State University. Initial velocities for Src KD
and SH3SH2KD (methylated and unmethylated) were measured
using a generic peptide substrate, poly(Glu,Tyr), as previously
described.34
NMR Spectroscopy. NMR spectra were acquired at 25 °C on a
Bruker AVII700 spectrometer with a 5 mm HCN z-gradient cryoprobe
operating at 1H frequency of 700.13 MHz using standard protocols
(Bruker pulse program hsqcetgpsp.2 and trosyf3gpphsi19). Sample
concentration was 135 μM ([13C]-methylated Src SH3SH2KD and
KD) or 200 μM (methylated and unmodiﬁed [15N]-Src KD) in the
following buﬀer: 50 mM bicine pH 8.0, 100 mM NaCl, 2 mM DTT,
5% glycerol, and 0.02% NaN3. SH3 ligand VSLARRPLPPLP was
purchased from GenScript, and SH2 ligand Caﬀeic acid-pYEEIE was
from Tocris Bioscience. The 13C reductively methylated Src
SH3SH2KD titration sample was dialyzed against 500 mL of buﬀer
(50 mM bicine pH 8.0, 100 mM NaCl, 2 mM DTT, 5% glycerol,
0.02% NaN3), changed each day for 7 days prior to acquisition of the
[1H,13C] HSQC spectrum. For AMP-PNP binding experiments,
MgCl2 was added to the
15N-labeled Src KD samples (methylated and
unmodiﬁed) to a ﬁnal concentration of 10 mM. B43 was purchased
from Calbiochem and dasatinib was purchased from Selleckchem.
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Additional characterization of the reductively methylated
proteins used in this study, as well as further information on
resonance assignments, ATP binding, and ligand titration. This
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